溶栓药物通过激活体内纤溶系统，促使血栓溶解，防止器官或肢体的缺血性损害。目前溶栓药物主要用于心肌梗死，使梗死后的冠脉再通，降低死亡率。继链激酶和尿激酶之后，近来采用ＤＮＡ重组技术制备了多种具有不同药效学特征的新型溶栓药物。临床主要用于冠脉再通，以降低死亡 Thrombolytic drugs by activating the fibrinolytic system in vivo, to promote thrombolysis and prevent ischemic damage to organs or limbs. Thrombolytic drugs are currently used mainly for myocardial infarction, recanalization of the coronary artery after infarction, reduce mortality. Following streptokinase and urokinase, a variety of novel thrombolytic drugs with different pharmacodynamic profiles have recently been prepared using DNA recombination techniques. Clinical mainly used for coronary recanalization to reduce death